BPC-157: A Comprehensive Review of Its Therapeutic Potential

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a fragment of human gastric juice protein. Across more than two decades of preclinical investigation, it has emerged as one of the most extensively studied peptides in the regenerative-medicine research literature. This systematic review synthesises findings from over fifty published preclinical studies — predominantly rodent models, with a smaller number of in-vitro mechanistic experiments — and evaluates the consistency, biological plausibility, and translational implications of the reported effects. The peptide has been investigated in models of tendon and ligament injury, muscle crush trauma, gastrointestinal ulceration, inflammatory bowel disease, post-surgical anastomosis healing, central-nervous-system injury, and vascular dysfunction. The convergence of effects across such diverse tissue systems is itself notable and has driven interest in BPC-157 as a potential candidate for translational research. Mechanistically, the most consistently reported pathway involves modulation of the nitric-oxide (NO) system. Multiple research groups have demonstrated that BPC-157 administration influences endothelial NO synthase activity, restores impaired NO-mediated vasodilation in injured tissue, and accelerates angiogenic responses measured by capillary density and CD31-positive vessel counts in healing wound beds. A second well-characterised pathway involves growth-factor receptor expression: preclinical data suggest BPC-157 upregulates VEGF-receptor 2, FGF, and EGF in tendon fibroblasts and tenocytes, contributing to the accelerated tendon-to-bone healing observed in transected Achilles and rotator-cuff models. A third pathway relates to gastrointestinal cytoprotection. The earliest BPC-157 work, conducted in the 1990s in models of gastric and duodenal ulceration, showed that the peptide prevents NSAID-induced mucosal damage, reduces lesion area in alcohol-induced gastric injury, and accelerates healing of established ulcers. More recent investigations have extended these findings to colitis models, where oral BPC-157 reduces histopathological severity scores and inflammatory cytokine levels (TNF-alpha, IL-6) in DSS-induced colitis. The review also examines models of central-nervous-system injury, where BPC-157 has been reported to attenuate neurological deficits following experimental stroke and traumatic brain injury, with the proposed mechanism involving stabilisation of the blood-brain barrier and reduced cerebral oedema. In musculoskeletal models, the peptide's effect on tendon healing is among the most replicated findings: across at least eight independent studies, transected Achilles tendons treated with BPC-157 showed accelerated functional recovery, increased collagen organisation on histology, and improved biomechanical strength testing relative to vehicle controls. Importantly, the review highlights several limitations that constrain interpretation. First, the overwhelming majority of published work originates from a small number of research groups, raising replication-cohort concerns that are common in early-stage peptide research. Second, dosing protocols vary widely across studies — from single 10 ug/kg intraperitoneal injections to oral regimens of several hundred ug/kg per day — making cross-study synthesis difficult. Third, despite the reproducibility of effects in rodent models, no Phase 2 or Phase 3 human clinical trials have been published. The handful of human case-series reports in the grey literature and on clinical-trial registries lack the rigour required for therapeutic claims. Pharmacokinetic data in humans remain sparse: oral bioavailability is theoretically supported by the peptide's resistance to gastric acid degradation (a feature attributed to its origin in gastric juice), but absolute bioavailability, plasma half-life, and tissue distribution in humans have not been formally characterised in published peer-reviewed work. Safety signals in the preclinical literature are reassuring within the doses tested — no significant organ toxicity, no behavioural changes attributable to the peptide, and no haematological abnormalities have been reported. However, the absence of long-term carcinogenicity, reproductive toxicity, and immunogenicity data means safety conclusions must remain provisional. The review closes with a discussion of priorities for future research: standardised dosing across labs, independent replication outside the original research group, formal pharmacokinetic characterisation in humans, and properly powered placebo-controlled clinical trials in well-defined indications such as recalcitrant tendinopathy or moderate-severity inflammatory bowel disease. Until those data are available, BPC-157 should be regarded as a research-grade compound with strong preclinical signal but unproven human efficacy or long-term safety. The peptide remains unscheduled by the FDA for clinical use; it is not approved as a drug and is not legally compounded by US 503A or 503B pharmacies following the FDA's 2023 categorisation. All discussion in this review is presented strictly for research education and does not constitute medical guidance, dosing recommendations, or endorsement of off-label human use.